Aldeyra's Reproxalap Faces FDA Rejection, Stock Plummets
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 11 2025
0mins
Source: TipRanks
Aldeyra Therapeutics Inc's stock plummeted approximately 75% in premarket trading as it hit a 52-week low following another FDA rejection of its lead drug reproxalap.
The FDA issued a Complete Response Letter indicating that the New Drug Application for reproxalap lacked substantial evidence of efficacy in treating dry eye disease, raising significant concerns about the reliability of clinical trial findings. This marks the third rejection for reproxalap, which has faced ongoing challenges in demonstrating effectiveness in controlled studies. Aldeyra plans to request a Type A meeting with the FDA to discuss the next steps for approval, which could have critical implications for its drug development strategy.
The repeated failures in obtaining FDA approval have led to extreme market pessimism regarding Aldeyra's future prospects, significantly impacting investor confidence and raising questions about the company's ability to secure future financing and continue its research efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALDX
Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.750
Low
9.00
Averages
9.50
High
10.00
Current: 1.750
Low
9.00
Averages
9.50
High
10.00
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, that May 29 is the critical deadline to apply as lead plaintiff, and failure to do so may result in loss of compensation rights.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden for investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements during the class period, particularly regarding the inconsistent results of its drug candidate reproxalap's clinical trials, which led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Aldeyra Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aldeyra Therapeutics on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026, indicating significant legal challenges that could impact the company's stock price and market confidence.
- Allegation Details: The lawsuit alleges that the defendants issued false and misleading statements and failed to disclose material adverse facts regarding Aldeyra's business and operations, particularly the inconsistency of reproxalap clinical trial results, which may have led to investor losses.
- Investor Rights Protection: Investors must apply by May 29, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the urgency of the legal process and its potential impact on investor decisions and future legal actions.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, underscoring its expertise and influence in protecting investor rights.
See More
Aldeyra Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between November 3, 2023, and March 16, 2026, with a deadline to contact the firm by May 29, 2026, for participation.
- False Statements Allegation: The complaint alleges that Aldeyra made misleading statements regarding the clinical trial results of its reproxalap drug candidate, which were inconsistent, rendering the company's positive assertions unreliable and leading to investor losses when the truth emerged.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to reach out before class certification to ensure their rights are protected and to avoid being absent class members.
- Market Reaction Impact: As the market becomes aware of Aldeyra's misleading statements, investor losses are expected to increase, highlighting significant deficiencies in the company's transparency and compliance, which could have long-term repercussions on its future financing and market trust.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, that May 29 is the crucial deadline to apply as lead plaintiff, and failure to do so may result in loss of compensation rights.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, misleading investors about the company's business and prospects, which ultimately led to financial losses, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and experience in handling similar cases.
See More
Aldeyra Therapeutics Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Aldeyra Therapeutics and certain officers, aiming to recover damages for investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, indicating strong investor concern over potential fraud.
- Detailed Allegations: The complaint alleges that defendants made false or misleading statements throughout the class period and failed to disclose inconsistencies in clinical trial results, rendering any purported positive findings unreliable and severely undermining investor confidence in the company's prospects.
- Urgent Action for Investors: Affected investors have until May 29, 2026, to request to be appointed as lead plaintiff, creating a sense of urgency for investors to act quickly to potentially share in any recovery from the lawsuit.
- Law Firm's Reputation: Bronstein, Gewirtz & Grossman, LLC is a well-regarded firm in securities fraud class actions, having recovered hundreds of millions for investors nationwide, showcasing its expertise and successful track record in handling such cases.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, that May 29 is the critical deadline to apply as lead plaintiff, and failure to do so may result in loss of compensation rights.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden for investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements during the class period, particularly regarding the inconsistent results of its drug candidate reproxalap's clinical trials, which led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Aldeyra Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aldeyra Therapeutics on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026, indicating significant legal challenges that could impact the company's stock price and market confidence.
- Allegation Details: The lawsuit alleges that the defendants issued false and misleading statements and failed to disclose material adverse facts regarding Aldeyra's business and operations, particularly the inconsistency of reproxalap clinical trial results, which may have led to investor losses.
- Investor Rights Protection: Investors must apply by May 29, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the urgency of the legal process and its potential impact on investor decisions and future legal actions.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, underscoring its expertise and influence in protecting investor rights.
See More
Aldeyra Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between November 3, 2023, and March 16, 2026, with a deadline to contact the firm by May 29, 2026, for participation.
- False Statements Allegation: The complaint alleges that Aldeyra made misleading statements regarding the clinical trial results of its reproxalap drug candidate, which were inconsistent, rendering the company's positive assertions unreliable and leading to investor losses when the truth emerged.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to reach out before class certification to ensure their rights are protected and to avoid being absent class members.
- Market Reaction Impact: As the market becomes aware of Aldeyra's misleading statements, investor losses are expected to increase, highlighting significant deficiencies in the company's transparency and compliance, which could have long-term repercussions on its future financing and market trust.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, that May 29 is the crucial deadline to apply as lead plaintiff, and failure to do so may result in loss of compensation rights.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, misleading investors about the company's business and prospects, which ultimately led to financial losses, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and experience in handling similar cases.
See More
Aldeyra Therapeutics Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Aldeyra Therapeutics and certain officers, aiming to recover damages for investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, indicating strong investor concern over potential fraud.
- Detailed Allegations: The complaint alleges that defendants made false or misleading statements throughout the class period and failed to disclose inconsistencies in clinical trial results, rendering any purported positive findings unreliable and severely undermining investor confidence in the company's prospects.
- Urgent Action for Investors: Affected investors have until May 29, 2026, to request to be appointed as lead plaintiff, creating a sense of urgency for investors to act quickly to potentially share in any recovery from the lawsuit.
- Law Firm's Reputation: Bronstein, Gewirtz & Grossman, LLC is a well-regarded firm in securities fraud class actions, having recovered hundreds of millions for investors nationwide, showcasing its expertise and successful track record in handling such cases.
See More
